Mutant onco-proteins as drug targets: Successes, failures, and future prospects

Current Opinion in Genetics and Development

Volumn 21, Issue 1, 2011, Pages 29-33

  McCormick, Frank ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BCR ABL PROTEIN; BEVACIZUMAB; CD135 ANTIGEN; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; IPILIMUMAB; JANUS KINASE 2; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MUTANT PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLX 4032; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN KINASE B; PROVENGE; RAS PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RITUXIMAB; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNIZATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MELANOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MUTANT PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 79551619150     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2010.12.002     Document Type: Review

References (32)

1. Nasr R., Lallemand-Breitenbach V., Zhu J., Guillemin M.C., de Thé H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res 2009, 15:6321-6326.
2. Sawyers C.L. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell 2002, 1:13-15.
3. Sawyers C.L. Calculated resistance in cancer. Nat Med 2005, 11:824-825.
4. Weisberg E., Sattler M., Ray A., Griffin J.D. Drug resistance in mutant FLT3-positive AML. Oncogene 2010, 16:5120-5134.
5. Reichardt P. Optimal use of targeted agents for advanced gastrointestinal stromal tumours. Oncology 2010, 78:130-140.
6. Garrido M.C., Bastian B.C. KIT as a therapeutic target in melanoma. J Invest Dermatol 2010, 130:20-27.
7. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
8. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
9. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
10. Michor F., Hughes T.P., Iwasa Y., Branford S., Shah N.P., Sawyers C.L., Nowak M.A. Dynamics of chronic myeloid leukaemia. Nature 2005, 435:1267-1270.
11. Sasaki T., Rodig S.J., Chirieac L.R., Janne P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010, 46:1773-1780.
12. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
13. Joseph E.W., Pratilas C.A., Poulikakos P.I., Tadi M., Wang W., Taylor B.S., Halilovic E., Persaud Y., Xing F., Viale A., et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 2010, 107:14903-14908.
14. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
15. Smalley K.S. PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Investig Drugs 2010, 11:699-706.
16. Yauch R.L., Dijkgraaf G.J., Alicke B., Januario T., Ahn C.P., Holcomb T., Pujara K., Stinson J., Callahan C.A., Tang T., et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009, 326:572-574.
17. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
18. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., Khuri F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005, 65:7052-7058.
19. Mirzoeva O.K., Das D., Heiser L.M., Bhattacharya S., Siwak D., Gendelman R., Bayani N., Wang N.J., Neve R.M., Guan Y., et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009, 69:565-572.
20. Stratton M.R., Campbell P.J., Futreal P.A. The cancer genome. Nature 2009, 458:719-724.
21. Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., et al. Signatures of mutation and selection in the cancer genome. Nature 2010, 463:893-898.
22. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
23. Singh A., Greninger P., Rhodes D., Koopman L., Violette S., Bardeesy N., Settleman J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
24. Faux M.C., Ross J.L., Meeker C., Johns T., Ji H., Simpson R.J., Layton M.J., Burgess A.W. Restoration of full-length adenomatous polyposis coli (APC) protein in a colon cancer cell line enhances cell adhesion. J Cell Sci 2004, 117:427-439.
25. Oda K., Okada J., Timmerman L., Rodriguez-Viciana P., Stokoe D., Shoji K., Taketani Y., Kuramoto H., Knight Z.A., Shokat K.M., et al. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res 2008, 68:8127-8136.
26. Cha E., Fong L. Therapeutic vaccines for prostate cancer. Curr Opin Mol Ther 2010, 12:77-85.
27. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
28. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., Yen Y., Heidel J.D., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
29. Luo J., Emanuele M.J., Li D., Creighton C.J., Schlabach M.R., Westbrook T.F., Wong K.K., Elledge S.J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
30. Barbie D.A., Tamayo P., Boehm J.S., Kim S.Y., Moody S.E., Dunn I.F., Schinzel A.C., Sandy P., Meylan E., Scholl C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112.
31. Friday B.B., Adjei A.A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008, 14:342-346.
32. Porfiri E., McCormick F. Regulation of epidermal growth factor receptor signaling by phosphorylation of the ras exchange factor hSOS1. J Biol Chem 1996, 271:5871-5877.